HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health...
News
Novartis blood disorder drug shows promise in late-stage trial
Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune...
Anne White to retire as head of Lilly Neuroscience after three decades at company
Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience,...
ANGLE partners with Myriad Genetics to explore blood-based cancer testing
ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system can be used alongside Myriad’s existing tissue-based diagnostic assays.
Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data
Friends of Cancer Research has announced a new collaboration with global clinical research organisation, MMS, to develop decision frameworks that will help interpret interim overall survival (OS) data in oncology trials.
Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford
Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support...
FDA grants Breakthrough Therapy Designation to lung cancer therapy
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab...
Ogsiveo approved in EU for treatment of desmoid tumors
Merck’s therapy becomes first authorised option for aggressive soft tissue tumours
Upperton and Oxford join forces to develop oral vaccine formulation
Project aims to improve global immunisation through needle-free delivery
Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection
Mounjaro shows cardiovascular benefit in head-to-head diabetes trial
Lilly’s study finds tirzepatide delivers broader health improvements
FDA approves AJOVY for paediatric migraine prevention
Teva’s CGRP therapy becomes first approved option for children and adolescent
Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Promising results support global submissions and priority review by US FDA
Lilly’s Jaypirca shows positive results in phase 3 trial
Pirtobrutinib meets primary endpoint in CLL/SLL study
Lilly and UK Government launch £85 million obesity care innovation programme
Nationwide competition to pilot new models of obesity support
